Delivery Order SPE2DR25D3015-SPE2DR26F4EW0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $4,244.31 under a firm fixed-price contract type. The award was made on May 6, 2025, with an ultimate completion date of May 7, 2025, and represents a non-set-aside competitive award. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $3,351.92 to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This is a firm fixed-price, non-set-aside contract to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $2,088.32 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 21 mg capsules (30-count package) on November 24, 2025, with completion expected by November 25, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $16,800.83 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) under a firm fixed-price contract. The award, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, represents a non-set-aside competitive award. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $12,137.10 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 21 mg capsules (30-count units). This firm fixed-price delivery order, which carries no set-aside designation, was competitively awarded and is set for completion by August 4, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) valued at $1,067.73 under a firm fixed price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and represents a non-competitive delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location, serving the federal medical supply chain...
- The Defense Logistics Agency awarded a delivery order contract valued at $36,356.83 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units). This was a competitively awarded, firm fixed-price delivery order with no set-aside designation, issued on November 17, 2025, with an ultimate completion date of November 18, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $9,609.57 delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count units) under a firm fixed price contract type. The award was made on August 13, 2025, with an ultimate completion date of August 14, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $43,416.77 to AmerisourceBergen Drug Corp for the supply of CAPLYTA 42 mg capsules (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract reflects no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, aligning with AmerisourceBergen's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $9,468.39 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of CAPLYTA 21 mg capsules (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of September 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DR25D3015Indefinite Delivery Contract
- SPE2DR25D3015-SPE2DR26F4EW0Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CAPLYTA 42 mg capsules (30-count) valued at $12,179.63 under a firm fixed-price contract. The award was made on November 24, 2025, with an ultimate completion date of November 25, 2025, and represents a non-set-aside competitive award. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order supports the Defense Logistics Agency's Medical Supply Chain operations and reflects AmerisourceBergen's role as a critical pharmaceutical vendor for federal military and veteran healthcare systems. AmerisourceBergen's prime IDV serves as a comprehensive global pharmaceutical support vehicle enabling the supply of a broad range of medications, including specialty pharmaceuticals, brand-name and generic drugs, and medical supplies to support military healthcare programs worldwide. This particular order for CAPLYTA, an atypical antipsychotic medication, demonstrates the company's capability to fulfill federal procurement requirements for specialized neurological medications across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.2k | 11/23/25 |